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Abstract
There is considerable interest in pneumococcal protein antigens capable of inducing serotype-independent immunopro-
tection and of improving, thereby, existing vaccines. We report here on the immunogenic properties of a novel surface
antigen encoded by ORF spr1875 in the R6 strain genome. An antigenic fragment encoded by spr1875, designated R4, was
identified using a Streptococcus pneumoniae phage displayed genomic library after selection with a human convalescent
serum. Immunofluorescence analysis with anti-R4 antisera showed that Spr1875 was expressed on the surface of strains
belonging to different serotypes. Moreover, the gene was present with little sequence variability in 27 different
pneumococcal strains isolated worldwide. A mutant lacking Spr1875 was considerably less virulent than the wild type D39
strain in an intravenous mouse model of infection. Moreover, immunization with the R4 recombinant fragment, but not with
the whole Spr1875 protein, induced significant protection against sepsis in mice. Lack of protection after immunization with
the whole protein was related to the presence of immunodominant, non-protective epitopes located outside of the R4
fragment. In conclusion, our data indicate that Spr1875 has a role in pneumococcal virulence and is immunogenic. As the R4
fragment conferred immunoprotection from experimental sepsis, selected antigenic fragments of Spr1875 may be useful for
the development of a pneumococcal protein-based vaccine.
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Introduction
Streptococcus pneumoniae, or pneumococcus, is an extracellular
human respiratory pathogen causing sinusitis, otitis media,
pneumonia, sepsis and meningitis. Invasive pneumococcal infec-
tions are an important cause of mortality and morbidity
worldwide, especially among young children and the elderly [1].
Pneumococci cause at least 1 million deaths worldwide every year,
mostly as a result of community-acquired pneumonia [2].
Moreover, antibiotic resistance is increasing at an alarming rate
among pneumococcal clinical isolates. The 23-valent polysaccha-
ride vaccine provides partial, serotype-specific protection in adults,
but has limited efficacy in young children. Although conjugate
vaccines are effective also in children, protection is limited to the
serotypes present in vaccine formulation and serotype replacement
is threatening to decrease vaccine efficiency. This is exemplified by
the increase, in the 7-valent vaccine era, of invasive disease caused
by strains of serotype 19A, a serotype not included in this vaccine
[3,4]. Therefore, the development of serotype-independent
vaccines targeting protein virulence factors is being actively
pursued and several pneumococcal proteins have been proposed
as potential vaccine candidates [5].
We have recently used a lambda phage displayed whole genome
library to identify several antigenic pneumococcal fragments,
based on their ability to bind to serum antibodies from patients
convalescing from pneumococcal infection or from experimentally
infected mice. This powerful approach allowed the identification
of a large panel of B-cell epitopes within known virulence factors
or protective antigens, including members of the choline-binding,
histidine-triad and zinc metalloproteinase families [6]. Further-
more, we identified new antigenic regions matching the sequence
of a novel pneumococcal adhesin, which was designated as
plasminogen and fibronectin binding protein B [7]. We report
here on the identification of a novel fragment designated as R4,
which is encoded by ORF spr1875 in the R6 genome. The spr1875
gene was found to be conserved amongst pneumococcal strains
isolated from different geographical areas. In an experimental
model of sepsis, a mutant strain devoid of Spr1875 was attenuated
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e36588in virulence. Moreover immunization with the R4 fragment of
Spr1875 conferred protection from intravenous challenge with
virulent pneumococci.
Results
Spr1875 is expressed on the bacterial surface
A lambda phage displayed library of the pneumococcal genome
(strain R6) was previously used to identify several antigenic
fragments based on their reactivity with human serum antibodies
[6]. By this approach, in the present study, we identified a novel
161 amino acid-long fragment, herein referred to as R4, using
serum antibodies from a patient convalescing from invasive
pneumococcal disease. The sequence matched ORF spr1875 of
the S. pneumoniae R6 strain genome (GenBank accession
no. AE007317), encoding a 380 amino acid-long protein with an
N-terminal peptidoglycan interaction lysine motif (LysM) domain,
which is found in cell wall degrading enzymes and in virulence
factors (Fig. 1). The predicted protein sequence of Spr1875
contains a leader peptide with a leader sequence and a cleavage
site present in variety of streptococcal surface proteins. We next
produced a recombinant R4-GST fusion protein and assessed its
ability to bind to serum antibodies from patients recovering from
pneumococcal infection. It was found that a high proportion of
such serum samples, but not control samples, displayed high anti-
R4 antibody titers (Table S1).
To assess whether the Spr1875 protein is actually expressed on
the bacterial surface, we used R4-GST to immunize mice. Mice
were also immunized with recombinant GST and CCR6, a crude
pneumococcal surface protein extract, to obtain negative and
positive control sera, respectively. Figure 2A (upper panels) shows
that sera from mice immunized with R4 fused to GST, but not
sera from mice immunized with GST alone, bound to the surface
of the rough R6 strain, or to an unencapsulated D39 mutant (D-
D39, Fig. 2A). Antibodies from CCR6-immunized mice positively
reacted with all strains tested, as expected. In addition, anti-R4
antibodies did not bind to the surface of the parental D39
encapsulated strain (Fig. 2A). These data indicate that Spr1875 is
expressed on the bacterial surface, but is largely masked by the
polysaccharide capsule.
Spr1875 is expressed in S. pneumoniae strains of different
serotypes
Next, we investigated whether Spr1875 is expressed in strains of
different pneumococcal serotypes. To this end, the unencapsulated
derivatives of TIGR4, 23F-Spain-1, and 19F-Taiwan-14 were
examined by immunofluorescence flow cytometry analysis using
anti-R4 mouse sera (Fig. 2A, lower panels). Anti-R4 antibodies
bound to the surface of each of these strains, indicating that
immunoreactive Spr1875 is expressed on pneumococcal strains of
different serotypes and geographical distribution. Next, we
compared the spr1875 gene sequences in 27 pneumococcal strains
using sequences available in DNA data bases. Figure 2B shows the
degree of sequence variability at different positions in the deduced
amino acid sequences. These sequences showed a remarkable
degree of conservation with no or only few variations at each
amino acid position. Such variations are mostly located in the
central portion and at the C- and N-terminal regions of the protein
sequence. A complete list of the aligned deduced amino acid
sequences is reported in Table S2 in supplemental material, which
shows that the 27 sequences belonged to one of 14 different
sequence types.
Spr1875 is required for in vivo pneumococcal growth
The pathogenicity of pneumococci has been attributed to
various virulence factors, mostly located on its surface. To evaluate
whether Spr1875 has an impact on pneumococcal virulence, we
constructed Dspr1875, a deletion mutant of the virulent,
encapsulated D39 strain. Spr1875 was not detectable, by western
blot, in Dspr1875 cell lysate using anti-R4 mouse serum (Fig. S1).
As a control, we also constructed DpspA, an isogenic D39 mutant
devoid of PspA, a well-characterized virulence factor that prevents
complement deposition on the bacterial surface [8]. Figure 3
shows survival plots of mice inoculated intravenously with the
wild-type D39 strain and Dspr1875 or DpspA mutants. Using the
lower bacterial doses (Fig. 3A and 3B), we observed markedly
increased survival in both Dspr1875- and DpspA-challenged mice,
as compared with the wild type D39 strain. The highest challenge
dose (7610
6 CFU) killed all mice within 5 days in each of the
D39-, Dspr1875-o rDpspA-infected groups (Fig. 3C). However,
with this dose, Dspr1875-infected mice had a significantly
Figure 1. Schematic structure and deduced amino acid sequence of protein Spr1875 of Streptococcus pneumoniae. (A) SP, signal
peptide; LysM, LysM peptidoglycan interaction domain. The extension of the fragment isolated from the phage display library (R4) is also indicated.
(B) Amino acid sequence of Spr1875, as deduced from ORF spr1875 in the strain R6 genome. The arrow indicates the predicted signal peptidase
cleavage site, according to SignalP v3.0 predictions. The LysM domain and the R4 fragment are indicated by the box and by the bold characters,
respectively.
doi:10.1371/journal.pone.0036588.g001
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mice. In each experiment, pneumococci were confirmed as the
cause of death by organ colony counts in moribund animals.
These data show that the spr1875-deficient strain is attenuated in
virulence, suggesting that the Spr1875 protein may play a role in
pneumococcal sepsis.
Protective activity of the R4 peptide fragment
To assess whether immunization with the recombinant R4
fragment had protection-eliciting activity against pneumococcal
infection, groups of mice were immunized with 50 mg of the R4-
GST fusion protein. After three administrations, all mice had R4-
specific serum antibody titers ranging from 1 8,000 to 1 64,000
(data not shown). R4-GST-immunized mice were challenged with
an approximately 90% lethal dose (1610
5 CFU) of the D39 strain.
Lethality was observed for 14 days and compared with that
observed in mice immunized with the GST tag only. Cumulative
data from three experiments indicated that immunization with the
R4-GST fragment resulted in 57% (16 mice out of 28) survival,
while only 18% (5 mice out of 28) of the GST-immunized animals
survived (p,0.05; Fig. 4A). Further data indicated that the
protection induced by immunization with R4-GST was antibody-
mediated, since it could be transferred to unimmunized animals by
pooled sera from animals immunized with R4-GST, but not from
those immunized with GST alone (Fig. S2).
We next recombinantly produced the whole Spr1875 protein
fused to a biotin (Spr1875-BIO) or to a GST (Spr1875-GST) tag
and used them for immunizing animals as in the experiments
described above. Surprisingly, neither Spr1875-BIO nor Spr1875-
GST immunization resulted in significant protection when
compared with immunization with the respective negative control
protein (Fig. 4B and Fig. S3). Based on these data we hypothesized
the induction of a different antibody response to the whole
Spr1875 protein as compared to immunization with the R4
fragment. To gain insights into the portion of the Spr1875 protein
against which serum antibodies were directed, we expressed a
recombinant fragment, designated R5, fused to GST (R5-GST).
This fragment encompassed the whole length of the Spr1875
protein excluding the R4 fragment (Fig. 5, upper panel). Next, we
conducted inhibition experiments in which R4-GST and R5-GST
were used to inhibit the reactivity of anti-Spr1875 serum
antibodies from Spr1875-BIO-immunized animals. In these
ELISA experiments, Spr1875-GST was used as a coating antigen
and antibody titers were measured in the presence and in the
Figure 3. Lethality induced in mice by a D39 mutant (Dspr1875)
lacking Spr1875. Wild type D39 and a mutant lacking PspA (DpspA)
were used as controls. CD1 mice were challenged intravenously with
3610
4 (A), 7610
4 (B) or 7610
6 (C) CFU. Results are from one experiment
per challenge dose involving 10 mice per group. *, statistically different
from D39 strain, as assessed by Kaplan-Meier estimator of survival.
doi:10.1371/journal.pone.0036588.g003
Figure 2. Surface expression of Spr1875 and spr1875 gene
polymorphism in different pneumococcal strains. (A) Immuno-
fluorescence flow cytometry analysis of different S. pneumoniae strains
using anti-R4-GST mouse serum (black lines). Anti-GST (grey peaks) and
anti-CCR6 (grey lines) murine sera were used as negative and positive
controls, respectively. D-D39, D-TIGR4, D-23F-Spain-1 and D-19F-
Taiwan-14 are unencapsulated mutants of D39, TIGR4, 23F-Spain-1
and 19F-Taiwan-14, respectively. (B). Schematic representation of
spr1875 deduced amino acid sequence variability within S. pneumoniae.
Twenty-seven strains were used for gene variability analysis. Abscissa,
amino acid position; ordinate, degree of polymorphism. The baseline
represents the sequence of the P1031 S. pneumoniae strain, which was
the longest sequence. The height of the line indicates the total number
of different amino acids found at that particular position.
doi:10.1371/journal.pone.0036588.g002
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reactivity of such sera was inhibited by R5-GST, while only 25%
was inhibited at saturation by R4-GST. The latter fragment,
however, completely inhibited reactivity of anti-Spr1875 antibod-
ies in sera from R4-GST-immunized animals (data not shown).
These data indicate that the large majority of serum antibodies
from animals immunized with the whole Spr1875 protein was
directed against the R5, and not the R4, portion of the molecule.
Protection induced by other Spr1875 fragments
We next hypothesized that antibodies directed against the R5
portion of the molecule were non-protective. To test this
hypothesis, animals were immunized with R5-GST, R4-GST or
with GST and challenged with the D39 strain as described above.
Indeed, in contrast with the results obtained with R4-GST, R5-
GST was totally unable to confer immunoprotection (Fig. 6A).
Collectively, these data indicated that immunization with the
whole Spr1875 protein induced antibodies predominantly directed
against immunodominant epitopes located in R5, a portion of the
molecule that does not contain protective epitopes.
Since these data indicated that Spr1875 has immunogenic
properties that may radically differ from those observed by using
its fragments, we recombinantly expressed three fragments of
approximately equal length covering the whole Spr1875 protein.
We designated these fragments as R1-GST, R2-GST and R3-
GST (Fig. 6, upper panel). The complete sequences of the
fragments are provided in Table S3 in the supplemental material.
As can be seen in Figure 6B, immunization with R2-GST, but not
R1-GST or R3-GST, was protective, and the degree of protection
was similar to that of R4-GST immunization. Thus, R4 and R2,
but not other portions of the Spr1875 molecule, appeared to
contain protective epitopes.
Discussion
The present study describes the identification and character-
ization of a novel protein antigen, Spr1875, and of recombinant
fragments encompassing the length of this protein. Spr1875 was
found to elicit antibodies in the course of human pneumococcal
infection, since it was identified by the ability of its R4 fragment to
bind antibodies in a convalescent serum. Moreover, further data
indicated that the R4 fragment is recognized by a high proportion
of sera from patients recovering from pneumococcal disease. Little
is presently know on the biological function of Spr1875. The
spr1875 gene was previously found to be strongly upregulated by
the VicR component of the VicRK two-component regulatory
system together with three other genes encoding one known
virulence factors (pspA) and putative membrane (spr0709) and cell
wall (spr0096) proteins [9]. Interestingly, Spr0096 and Spr1875 are
the only two proteins in S. pneumoniae to contain LysM
peptidoglycan-binding motifs. Several LysM proteins are known
to be virulence factors and/or protective antigens of human
bacterial pathogens and some function as adhesins [10]. For
example, Staphylococcus aureus produces five LysM proteins, which
are all involved in virulence [10,11]. Similar to Spr1875, protein
Figure 4. Protection induced by immunization with recombi-
nant R4-GST or by the whole recombinant Spr1875 protein
fused to a biotinylated tag (Spr1875-BIO). (A) Groups of CD1 mice
were immunized with R4-GST or with GST, used as a negative control,
and challenged with the D39 strain (1610
5 CFU). Results represent
cumulative data from 3 experiments; n=28, total number of animal per
each group. (B) Groups of CD1 mice were immunized with Spr1875-BIO
or with CAT-BIO, used as a negative control, and challenged with the
D39 strain (1610
5 CFU). Results represent data from one experiment
involving 14 animals per group. *, statistically different (p,0.05) from
mice challenged with D39 strain, as assessed by Kaplan-Meier estimator
of survival.
doi:10.1371/journal.pone.0036588.g004
Figure 5. The antibody response to recombinant Spr1875 is
predominantly directed against epitopes located outside of
the R4 fragment. Shown are inhibition ELISA experiments measuring
the reactivity against Spr1875-GST of a serum pool (with an antibody
titer of 1 16,000) from animals immunized with anti-Spr1875-BIO in the
presence of inhibitors. The recombinant Spr1875 fragments R4-GST and
R5-GST (see upper diagram) were used as inhibitors. Results are from
one experiment representative of three.
doi:10.1371/journal.pone.0036588.g005
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candidate for an S. agalactiae vaccine [12,13], contains one N-
terminal LysM domain.
In the first part of this study, we focused on the expression of the
spr1875 gene and on the impact of Spr1875 upon pneumococcal
virulence. Flow cytometry assays demonstrated that Spr1875 is
displayed on the surface of pneumococcal strains belonging to
different serotypes, although the presence of the polysaccharide
capsule largely masked the antigen. This is consistent with other
studies reporting that the pneumococcal capsule may mask to
varying degrees several surface proteins and adhesins [14,15].
Moreover, we found that the spr1875 gene was remarkably
conserved amongst serotypes and showed a low degree of
polymorphism. Virulence experiments demonstrated that
Spr1875 is required for in vivo pneumococcal growth, as evidenced
by the decreased ability of a Dspr1875 deletion mutant to produce
lethal infection in mice. The effects of such deletion were marked
and equalled or exceeded those observed with a DpspA deletion
mutant. Therefore our data indicate that Spr1875 may behave as
an important virulence factor, although further studies are clearly
needed to elucidate the function of this protein.
In the second part of the study, we focused on the
immunoprotective activity of Spr1875 and on its potential use as
a component of a protein-based vaccine. After immunization with
the recombinant R4 fragment, we observed significant protection
against lethal pneumococcal infection as 50–70% of R4-GST-
immunized mice were protected, while only 10–20% of GST-
immunized animals survived. In contrast, the whole Spr1875
protein was devoid of immunoprotective activity. This prompted
us to analyze in greater detail the nature of the antibody response
induced by whole Spr1875. It was found that 80–90% of the
reactivity of serum antibodies in Spr1875-immunized animals was
directed against the C-terminal portion of the molecule located
outside of the R4 fragment. Therefore, only low levels of anti-R4
antibodies were generated by Spr1875 immunization. Moreover,
we did not observe protective effects after immunization with a
recombinant fragment (R5-GST) encompassing the whole length
of the C terminal fragment external to R4. Thus, lack of
immunoprotection by the whole Spr1875 protein was linked to
the production of antibodies predominantly directed against non-
protective, immunodominant epitopes located outside of the R4
fragment. On the contrary, immunoprotection was associated with
the induction of anti-R4 antibodies.
Little is known on the molecular factors that determine the
immunodominance of some epitopes over others, although this
phenomenon is known to occur after immunization with virtually
any protein antigen [16]. It is generally thought that antigens
bearing immunodominant epitopes are attractive vaccine candi-
dates. However the opposite may be true. As recently noted [16],
from the pathogen standpoint it would be useful if the host
antibody response was directed against the non-protective portion
of a virulence factor containing potentially protective epitopes. In
other words, immunodominance of some protein regions may
reflect an immune evasion mechanism. In this case, it would be
appropriate, in terms of vaccine development, to redirect the
response against the non-immunodominant, protective portion of
an antigen, by synthesizing protein fragments that don’t
incorporate the immunodominant epitopes. This seemed to be
the case using Rib and a proteins of S. agalactiae and the M antigens
of S. pyogens, in which non immunodominant regions proved to be
of particular interest as vaccine components [16–18].
Interestingly, in the present study, another Spr1875 fragment
(designated as R2) showed, in addition to R4, protective activity
against pneumococcal infection after immunization. Since the R2
and R4 fragments overlap in a relatively short (54 aa long) portion
of the Spr1875 protein, our data raises the possibility that this
overlap region contains the protective epitope(s). Further studies
are clearly needed to test this hypothesis. Our data showing that
transfer of anti-R4 antibodies protected mice from lethal challenge
against the encapsulated D39 strain could, at first glance, appear
in contradiction with the inability of such antibodies to bind to the
surface of in vitro grown D39, due to the masking effect of the
capsule. However, it is likely that in vivo, at least temporarily or in
specific host microenvironments, capsular material is shed from
the bacterial surface and/or capsule expression is down-regulated,
resulting in exposure of underlying antigens. In support of this
notion, several surface pneumococcal antigens whose ability to
interact with host components is well documented, are inaccessible
to specific antibodies when grown in vitro [15].
In conclusion, we have identified a novel immunogenic surface
protein with an essential role in virulence. Although complete
protection was not observed, these data indicate that selected
fragments of the 1875 protein may help, in conjunction with other
Figure 6. Protection induced by immunization with recombi-
nant fragments of the Spr1875 protein. The diagram illustrates the
position of the various fragments relative to the whole protein. (A)
Protection induced by R5-GST in comparison with R4-GST. Groups of
CD1 mice were immunized with R4-GST, R5-GST or with GST, used as a
negative control, and challenged with the D39 strain (1610
5 CFU).
Results represent cumulative data from 3 experiments. A total number
of 28 animals were used for each group. (B) Groups of CD1 mice were
immunized with R1-GST, R2-GST, R3-GST or GST used as a negative
control, and challenged with the D39 strain (1610
5 CFU). Results
represent data from one experiment involving 14 animals per group.
*, statistically different (p,0.05) from D39 strain, as assessed by Kaplan-
Meier estimator of survival.
doi:10.1371/journal.pone.0036588.g006
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pneumococcal proteins.
Materials and Methods
Selection of the R4 fragment from the phage display
library
The R4 fragment was selected from a genomic pneumococcal
phage displayed library using previously described methods [6].
Pneumococcal strains
The following strains were used: 1) the encapsulated serotype 2
D39 strain [19] and its rough derivative R6 [20]; 2) the
unencapsulated mutants D-D39, D-Tigr4, D-23F-Spain-1, and
D-19F-Taiwan-14, which were kindly provided by Vega Ma-
signani (Novartis Vaccines and Diagnostics s.r.l., Siena, Italy). The
D39 deletion mutants DpspA and Dspr1875 (deleted for, respec-
tively, pspA (spr0121) and spr1875) were constructed using a
previously described procedure [21–23]; see also Text S1 and
Tables S2, S3, S4, and S5. Briefly, we first amplified by PCR an
antibiotic resistance gene and the 39 and 59 genomic regions
adjacent to the gene of interest. Next, these fragments were
assembled by PCR and the resulting product was used to
transform wild type D39 (relevant primers are reported in Table
S4 in supplemental materials). The mutants were verified by
sequencing (Table S5 in supplemental materials). All bacteria were
grown at 37uC in Todd-Hewitt broth (THB, Oxoid). When
necessary, chloramphenicol (3 mg/ml) and erythromycin (1 mg/ml)
were added. Neither the DpspA, nor the Dspr1875 strain differed
from the wild-type D39 strain in its ability to grow in Todd-Hewitt
broth.
Immunization and challenge
To study the protective activity of recombinant proteins, CD1
mice (5 wk old) were immunized intraperitoneally with 50 mgo f
recombinant proteins fused to glutathione S-transferase (GST) in
complete (first injection) or incomplete (second and third
injections) Freund’s adjuvant emulsions (0.2 ml) on day 0, 14,
and 28. Control animals received GST only. The use of complete
Freund’s adjuvant in the first immunization was justified by our
previous observations that high titered sera were more consistently
obtained with this adjuvant, as compared to other less ‘‘inflam-
matory’’ adjuvants such as alum. However, care was taken to
minimize discomfort to the animals by injecting a low volume
(0.1 ml containing 0.05 mg of mycobacteria) of the oily compo-
nent of the emulsion and by using sterile solutions and techniques
to prepare it. Under these conditions no significant abdominal
distension or complications at the injection site were observed
throughout the experimental period. Three weeks after the last
immunization mice were challenged i.v. with an approximately
90% lethal dose of D39 S. pneumoniae strain (1610
5 CFU) and
monitored for up to14 days. To determine the virulence of
deletion mutants pneumococcal strains were grown to mid log
phase (OD600=0.4). Bacteria were washed, resuspended in PBS
and plated for colony counts. Eight-week old CD1 mice were
inoculated intravenously with 0.1 ml of suspensions containing the
indicated bacterial doses. Signs of disease (e.g. rough hair,
decreased mobility, lethargy) and lethality were recorded daily
for 14 days and animals showing signs of irreversible disease were
humanely euthanized. Overwhelming S. pneumoniae infection was
confirmed as the cause of death by culturing the organs of
moribund animals.
For the passive protection experiment, each 8-week-old CD1
mouse received i.p. 50 ml of pooled sera from R4-GST-immunized
or GST-immunized mice. Four hours later, mice from both groups
were challenged i.v. with the D39 strain and survival was
monitored as described above. All in vivo experiments were
conducted at the animal facilities of the Metchnikoff Department
of the University of Messina according to the European Union
guidelines for the handling of laboratory animals and were
approved by the relevant local (Comitato Etico per la Sperimen-
tazione Animale) and national (Istituto Superiore di Sanita ` Permit
Numbers: 121/2007 - B) authorities.
Flow cytometry immunofluorescence and western blot
analysis
S. pneumoniae strains grown to the early-log phase (OD600=0.2)
were harvested by centrifugation, washed three times with PBS
and blocked for 20 min at 20uC with PBS containing 2% fetal calf
serum (PBS-FCS). Mouse antisera were diluted 1 100 in PBS-FCS
and incubated with bacterial cells for 40 min at 4uC. Phycoery-
thrin-conjugated goat anti-mouse IgG (Jackson Immunoresearch),
diluted 1 50 was then added to the cells and incubated at 4uC for
additional 30 min. Bacteria were then washed, fixed by parafor-
maldehyde and analyzed with an LSR Flow Cytometer using the
CellQuest software (both from BD Biosciences). Western blots
were performed using anti-R4 sera on bacterial cell lysates exactly
as described [6].
Production of recombinant fragments and antisera
The R4 recombinant fragment was amplified from a phage
clone and subcloned into the bacterial expression vector pGEX-
SN, a previously described expression vector [24] to produce
pGEX-SNR4 that allows the expression of recombinant proteins
as fusions to GST. Similarly, to produce the GST fusion fragments
R1 (117aa; E24-S140), R2 (124aa; Q141-K264), R3 (116aa; S265-
G380), and R5 (186aa; T195-G380) of the Spr1875 protein, or to
produce the whole Spr1875 protein fused to GST, the corre-
sponding DNA sequences were amplified from the R6 genome
and cloned into pGEX-SN. After induction of the fusion proteins,
recombinant fragments were purified from the soluble lysate of
bacterial cells by affinity chromatography [6]. Recombinant GST,
to be used as a control, was also produced using the same
procedures. The whole Spr1875 protein was also produced as a
polypeptide fused to a biotinylable peptide tag (BIO) in Escherichia
coli JM109, using the PinPoint Xa-1 Vector (Promega) according
to manufacturer’s instructions. After the induction of fusion
protein, this was purified from the cytoplasm of bacterial cells by
affinity chromatography using the PinPointXa protein purification
system (Promega). Recombinant chloramphenicol acetyl transfer-
ase fused to biotin (CAT-BIO), to be used as a negative control,
was produced and purified using the same methods.
Determination of R4-specific serum antibody titers
Anti-R4 serum antibody titers in immunized mice were
measured by a previously described ELISA method [25]. Briefly,
wells of microtiter plates were sensitized with R4-GST fusion
protein (5 mg/ml). Mouse sera were serially diluted with antibody
buffer containing 25 mg/ml of GST to block non-specific anti-
GST antibodies. Serial serum dilutions were reacted for 2 h at
37uC before the addition of a 1 5,000 dilution of goat anti-mouse
polyvalent IgG conjugated to alkaline phosphatase (Sigma). Plates
were then developed, as described [25]. Antibody titers in human
sera were measured by a similar ELISA assay, except that sera
were diluted in plain antibody buffer (i.e. without GST) and an
anti-human, instead of an anti-mouse, anti-IgG conjugate was
used.
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To obtain anti-pneumococcal immune sera, to be used as
positive controls, a group of mice was immunized with a cho-
line binding proteins-enriched fraction designated as CCR6.
CCR6 was obtained from strain R6 cells grown to the early
exponential phase (OD600=0.2), washed with phosphate
buffered saline (PBS; pH 7.2), and incubated in the presence of
2% choline chloride (Sigma) at 20uC for 10 minutes. The
supernatant was dialyzed, concentrated and used as described
above to immunize mice using 50 mg (total protein content) for
each immunization.
Inhibition ELISA
These experiments were performed to assess the ability of
recombinant protein fragments to inhibit the reactivity of
anti-Spr1875 sera against the homologous antigen. To this end,
mouse sera raised against Spr1875-BIO were reacted against
Spr1875-GST. An anti-Spr1875-BIO serum pool (diluted
1 200 in PBS-FCS) was added to microtiter wells sensized with
Spr1875-GST (1 mg/ml in PBS) in the presence and in the
absence of the indicated concentrations of inhibitors (i.e. R4-
GST and R5-GST). After washing with PBS-FCS, alkaline
phosphatase-conjugated goat anti-mouse IgG (Sigma) was
added at a 1 5000 dilution followed by p-nitrophenyl phosphate
disodium salt (Sigma). Percent of inhibition was calculated by
comparing the absorbance value of wells with and without the
inhibitors.
Supporting Information
Figure S1 Lack of Spr1875 in cell lysates from the
Dspr1875 pneumococcal strain. D39 or Dspr1875 cell lysates
were loaded on a polyacrylamide gel and developed with anti-R4
mouse serum (1 1,000). The arrow indicates the 40 kDa Spr1875
protein in the D39, but not in the Dspr1875,cell lysate.
(TIF)
Figure S2 Protection induced by R4 immunization is
mediated by serum antibodies. Two groups of 16 mice each
were given i.p. 50 ml of serum pools from animals immunized with,
respectively, GST (anti-GST) or R4-GST (anti-R4-GST). After
4 h both groups of animals were challenged i.v., with D39
(1610
5 CFU). *, statistically different (p,0.05) from animals given
anti-GST serum as assessed by Kaplan-Meier estimator of
survival.
(TIF)
Figure S3 Lack of protection induced by immunization
with recombinant Spr1875 protein fused to a GST tag
(Spr1875-GST). (A) Groups of CD1 mice were immunized with
Spr1875-GST or with GST, used as a negative control, and
challenged with the D39 strain (1610
5 CFU). Results represent
data from one experiment involving 8 animals per group.
(TIF)
Table S1 Anti-R4 Elisa titers of sera from patients
convalescing from pneumococcal infection.
(DOC)
Table S2 Alignment of 27 S. pneumoniae strain se-
quences available in DNA database using the ClustalW
software (http://www.ebi.ac.uk/Tools/clustalw2/
index.html).
(DOC)
Table S3 Amino acid sequences of Spr1875 fragments.
(DOC)
Table S4 Primers used in the construction of DpspA and
Dspr1875 deletion mutants.
(DOC)
Table S5 Genomic replacement sequences for DpspA
and Dspr1875 deletion mutants.
(DOC)
Text S1 Supplemental Materials and Methods.
(DOC)
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